Bargiela D, Bianchi MT, Westover B, et al. Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis. Neurology. 2017;88(7):677-684. doi:10.1212/WNL.0000000000003612.

Lane WJ, Westhoff CM, Gleadall NS, et al. Automated typing of red blood cell and platelet antigens: a whole-genome sequencing study. Lancet Haematol. 2018;5(6):e241-e251. doi:10.1016/S2352-3026(18)30053-X.

Penney KL, Stampfer MJ, Jahn JL, et al. Gleason grade progression is uncommon. Cancer Res. 2013;73(16):5163-8. doi:10.1158/0008-5472.CAN-13-0427.

Tyekucheva S, Martin NE, Stack EC, et al. Comparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues. J Mol Diagn. 2015;17(4):374-81. doi:10.1016/j.jmoldx.2015.02.002.

Van Allen EM, W Y Lui V, Egloff AM, et al. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. JAMA Oncol. 2015;1(2):238-44. doi:10.1001/jamaoncol.2015.34.

Townsend EC, Murakami MA, Christodoulou A, et al. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016;29(4):574-86. doi:10.1016/j.ccell.2016.03.008.